Description

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Cancer-programmed cell death–C35H57N13O14S2—-[1]Puig-Saus C, et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 2014 Aug;21(8):767-74.|[2]Zhang L, et al. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother. 2017 Sep;93:1136-1143.–1392278-76-0–948.04–99.57–O=C([C@@H](N)CSSC[C@H](NC1=O)C(O)=O)N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H]1CC(O)=O)=O)CCC2)=O)=O)CCCCN)=O)CC(O)=O)=O)=O)CCCNC(N)=N–Cancer–H2O : ≥ 50 mg/mL–Integrin—-Cytoskeleton–Peptides